This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking on the systemic mastocytosis landscape with a focus on the potential of Ayvakit (avapritinib), BLU-263, and Bezuclastinib (CGT9486/ PLX9486)

Ticker(s): BPMC, COGT

Who's the expert?

Institution: MD Anderson

  • Associate Professor of Medicine, Department of Leukemia at MD Anderson.
  • Manages 40 patients with systemic mastocytosis.
  • Research focus is on myeloproliferative neoplasms (MPNs). Heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research; leads number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis (PI on APEX, SUMMIT, HARBOR).

Interview Questions

Please describe your clinical practice; roughly how many patients with systemic mastocytosis do you currently manage?

Added By: joe_mccann

What % of your patients do you believe are a good candidate for Ayvakit?

Added By: joe_mccann

What is the treatment paradigm of aggressive SM now with Ayvakit approved? What is the treatment paradigm of indolent SM?

Added By: joe_mccann

What % of patients do you plan to prescribe Ayvakit to? Any difference in usage for aSM vs. SM with hematologic neoplasm vs. mast cell leukemia? Are there any patients you are using Midostaurin ahead of Ayvakit?

Added By: joe_mccann

What are your thoughts on the label? Any concerns with the Intracranial Hemorrhage warning?

Added By: joe_mccann

Has the cost of the drug posed any issues for reimbursement yet? $400K annual list price

  • What is your best estimate for the total annual drug cost for your typical iSM patient today? Do you think Avapritinib’s current price of $400K/year will be a barrier to use in iSM?

Added By: joe_mccann

How do you currently treat iSM patients? What % of patients are you able to control symptoms with currently available treatment options?

Added By: joe_mccann

What is the remaining unmet need in iSM?

Added By: joe_mccann

What are your thoughts on the initial avapritinib data in iSM patients from PIONEER?

Added By: joe_mccann

What % of your iSM patients could benefit from avapritinib? If approved and the profile is consistent with reported data, what % of patients would you prescribe it to?

Added By: joe_mccann

Are you familiar with the recent Celldex data for its anti-KIT antibody in a couple other mast cell diseases? Do you have any views on whether this drug could be a viable treatment in iSM given the strong reductions in skin mast cells and serum tryptase?

Added By: joe_mccann

Are any other development candidates in iSM interesting to you?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.